- Home
- LSF vs IMRX Comparison
LSF vs IMRX Comparison
Compare LSF & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSF
- IMRX
- Stock Information
- Founded
- LSF 2015
- IMRX 2008
- Country
- LSF United States
- IMRX United States
- Employees
- LSF N/A
- IMRX N/A
- Industry
- LSF Packaged Foods
- IMRX Biotechnology: Pharmaceutical Preparations
- Sector
- LSF Consumer Staples
- IMRX Health Care
- Exchange
- LSF Nasdaq
- IMRX Nasdaq
- Market Cap
- LSF 90.1M
- IMRX 73.2M
- IPO Year
- LSF 2020
- IMRX 2021
- Fundamental
- Price
- LSF $8.25
- IMRX $1.78
- Analyst Decision
- LSF Strong Buy
- IMRX Buy
- Analyst Count
- LSF 2
- IMRX 7
- Target Price
- LSF $7.75
- IMRX $12.80
- AVG Volume (30 Days)
- LSF 105.2K
- IMRX 801.9K
- Earning Date
- LSF 11-06-2024
- IMRX 11-13-2024
- Dividend Yield
- LSF N/A
- IMRX N/A
- EPS Growth
- LSF N/A
- IMRX N/A
- EPS
- LSF N/A
- IMRX N/A
- Revenue
- LSF $40,896,326.00
- IMRX N/A
- Revenue This Year
- LSF $21.72
- IMRX N/A
- Revenue Next Year
- LSF $10.16
- IMRX N/A
- P/E Ratio
- LSF N/A
- IMRX N/A
- Revenue Growth
- LSF 20.33
- IMRX N/A
- 52 Week Low
- LSF $0.71
- IMRX $1.00
- 52 Week High
- LSF $10.90
- IMRX $8.07
- Technical
- Relative Strength Index (RSI)
- LSF 48.51
- IMRX 37.40
- Support Level
- LSF $7.55
- IMRX $1.52
- Resistance Level
- LSF $8.51
- IMRX $1.93
- Average True Range (ATR)
- LSF 0.70
- IMRX 0.19
- MACD
- LSF -0.19
- IMRX -0.05
- Stochastic Oscillator
- LSF 21.79
- IMRX 21.95
About LSF Laird Superfood Inc.
Laird Superfood Inc is engaged in the business of manufacturing and marketing differentiated plant-based and functional foods. The product portfolio includes Coffee creamers, Hydration products and beverage-enhancing supplements, Harvest snacks and various other food items, and Coffee, tea, and hot chocolate products.
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.